Immunotherapy and bevacizumab for advanced ovarian clear cell cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 and under 75 years old.
- You must have been diagnosed with ovarian clear cell carcinoma that has not spread too far (stage IC to IV).
- You must be scheduled for surgery to remove the tumor (primary debulking surgery).
- You cannot have received any chemotherapy, immunotherapy, or targeted therapy for this cancer before.
- Your kidney, liver, and blood cell counts must meet certain minimum levels.
- You cannot have an active autoimmune disease, uncontrolled infection, or serious heart condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs — liposomal irinotecan (a type of chemotherapy), sintilimab (an immunotherapy that helps your immune system fight cancer), and anlotinib (a targeted therapy that blocks blood vessels feeding the tumor) — for women with ovarian clear cell carcinoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink or control the cancer better than existing options.
This trial tests a combination of three drugs (RC48, AK104, and bevacizumab) for ovarian clear cell carcinoma, a type of ovarian cancer. The goal is to see if this combination can help shrink or control the cancer in people who have not had many prior treatments.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial tests a combination of two immunotherapy drugs, bevacizumab, and chemotherapy given before surgery for advanced ovarian cancer. The goal is to shrink tumors to make surgery more effective and potentially improve outcomes.
This study tests a new drug (BG-C9074) combined with a standard targeted therapy (bevacizumab) for women newly diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding this new drug can help shrink or control the cancer better than the standard approach alone.
Hear when a new Ovarian Clear Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.